Researchers from the George Washington University and the Washington DC Veterans Affairs Medical Center have published a case ...

There are a handful of patients in DESTINY-Breast03 with active brain metastasis that were enrolled, and they did look and ...

A systematic review of randomized controlled trials (RCTs) found that weight-loss interventions were associated with improvements in some polycystic ovary syndrome (PCOS) symptoms, including ...

After chemotherapy failure, if the cancer is also resistant to endocrine therapy, patients face a double obstacle: few ...

The FDA approved zolbetuximab (Vyloy) on October 18, 2024, as a first-line treatment for locally advanced unresectable or ...

She focused on 2 FDA-approved antibody drug conjugates (ADCs): trastuzumab deruxtecan (T-DXd; Enhertu; Daiichi Sankyo/AstraZeneca) and sacituzumab govitecan (SG), which have both demonstrated ...

Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long ...

Anti-HER2 antibody-drug conjugates (ADCs) have proven effective in multiple tumor types. However, between 64% and 85% of HER2+ breast and gastric cancer patients retain HER2 expression after treatment ...

Trastuzumab deruxtecan (T-DXd; Enhertu) is an antibody-drug conjugate used as standard therapy for HER2-positive and HER2-low unresectable or metastatic breast cancer. 1 It is classified by the ...